ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development Accelerates.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Bundibugyo virus is one of the viruses in the genus Orthoebolavirus and was first identified in 2007 during an Ebola outbreak in the Bundibugyo District of western Uganda. In early May 2026, the World Health Organization (WHO) was alerted to an outbreak of Bundibugyo virus in the Ituri province of north-eastern Democratic Republic of Congo (DRC), with cases also reported in the nearby North Kivu and South Kivu provinces, and some imported cases with limited local transmission in Uganda. On May 17, 2026, the WHO declared the ongoing outbreak of Ebola disease caused by the Bundibugyo virus a Public Health Emergency of International Concern (PHEIC). The latest WHO data on June 19, 2026, showed that by June 17, 2026, the cumulative number of confirmed cases had risen to 896, including 232 deaths (a fatality rate of 26%), indicating that supportive treatments alone were not reducing mortality. Currently, there are no licensed vaccines with a specific indication for the prevention of Bundibugyo virus infection. On June 1st, 2026, the Coalition for Epidemic Preparedness Innovations (CEPI) announced its recommendations to urgently accelerate the development of three investigational vaccines targeting the Bundibugyo Ebola virus, including the candidate vaccine, ChAdOx1 BDBV. On June 3, 2026, the European Medicines Agency (EMA), the African Medicines Agency (AMA), and African regulatory authorities issued a joint response to the ongoing Ebola outbreak in the DRC and Uganda, drawing on expertise from the WHO-AFRO African Vaccines Regulatory Forum (AVAREF). This editorial provides background on the current acceleration in vaccine development and the urgency of this response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.